Sarepta Therapeutics

SRPT

Market cap $1.82B

SRPT Hedge Fund Activity: Q1 2026 in Review

339 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2026, worth a combined $2.23B — up 11% from $2.01B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new SRPT positions and 46 closed out — a net gain of 3 holders — while 109 added to existing stakes and 128 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $75.5M. The largest seller was AQR Capital Management, cutting an estimated $26.4M.

• 339 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2026, down from 344 in Q4 2025.
• Funds reported $2.23B of Sarepta Therapeutics stock for Q1 2026, up 11% quarter-over-quarter.
• 49 funds opened new Sarepta Therapeutics positions in Q1 2026 and 46 closed out, a net change of +3 holders.
• The largest Sarepta Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $75.5M added.
• The largest Sarepta Therapeutics seller in Q1 2026 was AQR Capital Management, an estimated $26.4M sold.

Based on aggregated 13F filings for Q1 2026.